Matinas biopharma reports q2 loss per share $0.03

Matinas biopharma reports second quarter 2020 financial results and operational highlights.q2 loss per share $0.03.q2 earnings per share estimate $-0.03 -- refinitiv ibes data.matinas biopharma holdings- enhance-it study of mat9001 against vascepa expected to be fully enrolled in aug 2020; topline data anticipated q1 2021.matinas biopharma holdings - enact study of mat2203 in cryptococcal meningitis resumed enrollment; on track for potential cohort progression q4 2020.
MTNB Ratings Summary
MTNB Quant Ranking